Pherecydes Pharma Overview
Founded
2006
Status
Private
Employees
12
Latest Deal Type
Grant
Latest Deal Amount
$2.99M
Investors
11
Pherecydes Pharma General Information
Description
Developer of therapeutic biotechnologies intended to treat bacterial infections. The company's biotechnologies develops bacteriophages against infections, evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 22, Boulevard Bénoni Goullin
- 44200 Nantes
- France
+33 02 00 00 00 00
Pherecydes Pharma Timeline
Pherecydes Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Grant | 01-Feb-2018 | $2.99M | 000.00 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series B) | 16-Jan-2018 | 000.00 | 000.00 | Completed | Generating Revenue | |
| 4. Later Stage VC (Series A) | 18-Mar-2015 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 3. Grant | 18-Jan-2012 | 00.000 | 00.000 | Completed | Startup | |
| 2. Angel (individual) | 01-Jan-2007 | $3.03M | $3.03M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Pherecydes Pharma Competitors (15)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 0000000000 | 00000 |
| 00000 | Formerly VC-backed | Ness Ziona, Israel | 00 | 00000 | 00000000000 | 00000 |
| 00000000 | Angel-Backed | Boston, MA | 0 | 00.000 | 0000000000 | 00.000 |
| 00000000 | Venture Capital-Backed | Cambridge, MA | 0 | 000.00 | 00000000000 | 000.00 |
| 00 00000000 | Private Debt Financed | Paris, France | 00 | 000.00 | 000000000 | 000.00 |
Pherecydes Pharma Executive Team (6)
2 Former Executives
Pherecydes Pharma Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Claire Poulard | Omnes Capital | Supervisory Board Member | 000 0000 |
| Didier Hoch | Self | Chairman | 000 0000 |
| Emmanuelle Coutanceau Ph.D | Auriga Partners (Paris) | Board Member | 000 0000 |
| Franck Lescure Ph.D | Auriga Partners (Paris) | Supervisory Board Member | 000 0000 |
| Leila Guerlain Nicolas | GO Capital (France) | Supervisory Board Member | 000 0000 |
Pherecydes Pharma Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Horizon 2020 | Government | 000 0000 | 000000 0 | ||
| Elaia Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| FaDiese | Venture Capital | Minority | 000 0000 | 000000 0 | |
| GO Capital (France) | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Omnes Capital | PE/Buyout | Minority | 000 0000 | 000000 0 |
Ready to get started?
Request a free trial